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Introduction
HIV is a viral infection that attacks the body’s immune system.
Although antiretroviral therapy is currently used to maintain a
low viral load, no cure has been discovered for HIV. This research
sought to explore a combination of gene therapy and latency re-
versing agents as a potential functional cure for HIV patients.
We begin by building a system of differential equations to model
an HIV infection under the combined treatment of CRISPR-Cas9
gene therapy, latency reversing agents (LRA), and antiretroviral
therapy (ART). We then solve the corresponding optimal control
problem to seek a functional cure by extending the remission time
between treatments. The model presented below, based on the
work found in [1, 2], describes the interactions between CCR5−
cells, Tu, CCR5+ cells, TS, latently infected cells, L, actively in-
fected cells I , and free virions V .
The Model
dTu
dt
= λf − δTTu
dTs
dt
= λ(1− f )− δTTs − βTSV
dL
dt
= εβTsV − (α + η + δ)L + γI
dI
dt
= (1− ε)βTsV − (δ + c + γ)I + (α + η)L
dV
dt
= pI − cV
Basic Reproductive Ratio
We denote the disease-free equilibrium by E0 =
T 0u, T
0
s , 0, 0, 0
 =
λf
δT
,
λ(1− f )
δT
, 0, 0, 0
 and calculate R0 using the next generation
matrix method:
R0 =
βλp(1− f )(α + η + δ(1− ε))
δTδV ((α + η + δ)(c + δ) + δγ)
.
Global Stability
Theorem: When R0 ≤ 1, the disease free equilibrium
T 0u, T
0
s , 0, 0, 0
 is globally
asymptotically stable.
To prove this theorem, we constructed the following Lyapunov function
L(Tu, Ts, L, I, V ) =
Tu − T
0
u − T 0u ln

Tu
T 0u

 +
Ts − T
0
s − T 0s ln

Ts
T 0s


+ α + η
α + η + (1− ε)δ
L + α + δ + η
α + η + (1− ε)δ
I + βλ(1− f )
δTδV
V.
Theorem: When R0 > 1, the endemic equilibrium, denoted by
(T ∗u , T ∗s , L∗, I∗, V ∗), is globally asymptotically stable.
To prove this theorem, we constructed a Lyapunov function similar to the one above:
L =
Tu − T
∗
u − T ∗u ln

Tu
T ∗u

 +
Ts − T
∗
s − T ∗s ln

Ts
T ∗s

 +

α + η
α + η + (1− ε)δ

L− L∗ − L∗ ln

L
L∗


+

α + η + δ
α + η + (1− ε)δ

I − I∗ − I∗ ln

I
I∗

 +

βT ∗s
δV

V − V ∗ − V ∗ ln

V
V ∗

 .
Optimal Control
Emphasizing a reduction in the latent reservoir, we find the following optimal func-
tions f (t), α(t), and c(t) that minimize the cost and side effects of gene therapy and
LRA efficacy.
Numerical Results
Our simulations found that an optimal efficacy of gene therapy
alone reduces the viral load by roughly 15% while a combina-
tion treatment of gene therapy and LRA reduces the viral load
by roughly 50%. Additionally, we found that the latent reservoir
was reduced by roughly 20% with gene therapy alone, but with a
combination treatment strategy, the latent reservoir was reduced
by a capacity of 80%.
Conclusion
Our results suggest that the use of gene therapy in conjunction
with LRA and ART treatments could provide longer remission
times compared to only one treatment option on its own. Current
feasible remission times for individuals undergoing ART therapy
is around seven days [1]. This fast relapse time creates a situation
where individuals are forced to constantly stay on ART therapy.
However, if the remission time could be prolonged, it could pro-
vide the opportunity for an individual with HIV to forgo ART
treatment for a noticeable period of time. In future research, we
hope to look at adding on other treatment strategies from [1] in
combination with gene therapy and/or LRA treatment to com-
pare the prolonged remission time found here with other potential
treatments.
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